Stable HCV E2 Polypeptide Expression in HEK293T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing HCV E2 polypeptides are inefficient, leading to low expression levels and poor quality, and there is a need for more effective vaccines and inhibitors against HCV infection.
Innovation Solution
A method involving a cytomegalovirus promoter, a fragment of HCV envelope 2 surface protein, and a cleavage site is introduced into HEK293T cells, allowing for stable expression and purification of full-length or fragment HCV E2 polypeptides with C-terminal tags, such as human Fc or protein-A, to produce high yields of properly folded proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If transient expression in non-human cells is used, then expression time is short, but productivity is low and expression levels are poor
Solution Approach 1:
The patent creates stable cell lines where the HCV E2 gene is permanently integrated into the host genome before expression begins. This preliminary integration ensures that the cells continuously produce high levels of E2 protein over extended periods, eliminating the need for repeated transfections and achieving both long-term expression and high productivity
Solution Approach 2:
The stable cell lines autonomously maintain and express the HCV E2 gene without requiring external intervention. The integrated gene serves itself by continuously directing protein synthesis, and the cells self-renew while maintaining expression capability, achieving sustained high-level production without additional transfection steps
2Device complexity
If no purification tag is used, then protein structure is simpler, but ease of manufacture is reduced due to purification difficulty
Solution Approach 1:
The patent introduces purification tags (such as Fc tags or His-tags) as intermediary elements attached to the HCV E2 protein. These tags serve as mediators that enable easy purification through affinity chromatography while being removable by proteolytic cleavage, thus facilitating manufacture without permanently altering the target protein structure
Solution Approach 2:
The patent segments the protein production process into two distinct phases: expression with tag attached for easy purification, and post-purification tag removal to restore the native protein structure. This segmentation allows optimization of each phase independently, achieving both ease of manufacture and correct final structure
3Reliability
If current HCV therapy is used, then treatment can clear virus in some patients, but side effects cause premature treatment cessation
Solution Approach 1:
The patent extracts and isolates the specific HCV E2 antigen component to create targeted vaccines and therapeutics. By focusing on this single viral protein, the invention aims to elicit specific immune responses against HCV without requiring the broad immunomodulation and associated side effects of interferon-alpha and ribavirin combination therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of high-quality HCV E2 polypeptides that are conformationally similar to the native protein, recognized by antibodies, and capable of inhibiting HCV cell entry or inducing antibody production, with yields ranging from 0.5 to 60 mg per liter of supernatant.
Implementation Method 1
A method involving a cytomegalovirus promoter, a fragment of HCV envelope 2 surface protein, and a cleavage site is introduced into HEK293T cells, allowing for stable expression
Data Source
AI summary
Methods of producing and using Hepatitis C virus (HCV) eE2 polypeptides are described.